title: Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
abstract: We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high.
authors.affiliation: IRD, UMR 145 (IRD/University of Montpellier 1), Montpellier, France. christian.Laurent@mpl.ird.fr
authors.forename: Christian
authors.initials: C
authors.lastname: Laurent
authors.forename: Charles
authors.initials: C
authors.lastname: Kouanfack
authors.forename: Sinata
authors.initials: S
authors.lastname: Koulla-Shiro
authors.forename: Maguy
authors.initials: M
authors.lastname: Njoume
authors.forename: Yvette Mawamba
authors.initials: YM
authors.lastname: Nkene
authors.forename: Laura
authors.initials: L
authors.lastname: Ciaffi
authors.forename: Charlotte
authors.initials: C
authors.lastname: Brulet
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Laurence
authors.initials: L
authors.lastname: Vergne
authors.forename: Alexandra
authors.initials: A
authors.lastname: Calmy
authors.forename: Eitel
authors.initials: E
authors.lastname: Mpoudi-Ngolé
authors.forename: Eric
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008134:Long-Term Care / Q000379:methods; D008297:Male; D019829:Nevirapine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine